V
Vandana G. Abramson
Researcher at Vanderbilt University
Publications - 141
Citations - 5675
Vandana G. Abramson is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 32, co-authored 122 publications receiving 3972 citations. Previous affiliations of Vandana G. Abramson include University of Pennsylvania & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy,Sherene Loi,Alicia Okines,Elisavet Paplomata,Erika Hamilton,Sara A. Hurvitz,Nan Lin,Virginia F. Borges,Vandana G. Abramson,Carey K. Anders,Philippe L. Bedard,Mafalda Oliveira,Erik Jakobsen,Thomas Bachelot,Shlomit S. Shachar,Volkmar Müller,Sofia Braga,François Duhoux,Richard Greil,David Cameron,Lisa A. Carey,Giuseppe Curigliano,Karen A. Gelmon,Gabriel N. Hortobagyi,Ian E. Krop,Sibylle Loibl,Mark D. Pegram,Dennis J. Slamon,M Corinna Palanca-Wessels,Luke Walker,Wentao Feng,Eric P. Winer +31 more
TL;DR: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo.
Journal ArticleDOI
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia,Ingrid A. Mayer,Linda T. Vahdat,Sara M. Tolaney,Steven J. Isakoff,Jennifer R. Diamond,Joyce O'Shaughnessy,Rebecca L. Moroose,Alessandro D. Santin,Vandana G. Abramson,Nikita C. Shah,Hope S. Rugo,David M. Goldenberg,Ala M Sweidan,Robert Iannone,Sarah A. Washkowitz,Robert M. Sharkey,William A. Wegener,Kevin Kalinsky +18 more
TL;DR: It is shown that sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer and was also associated with clinical benefit rate and overall survival.
Journal ArticleDOI
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty,Patricia LoRusso,Angela DeMichele,Vandana G. Abramson,Rachel Courtney,Sophia Randolph,Naveed Shaik,Keith D. Wilner,Peter J. O'Dwyer,Gary K. Schwartz +9 more
TL;DR: PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity, and was shown to be proportional to exposure using an Emax model.
Journal ArticleDOI
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial
Nan Lin,Virginia F. Borges,Carey K. Anders,Rashmi Krishna Murthy,Elisavet Paplomata,Erika Hamilton,Sara A. Hurvitz,Sherene Loi,Alicia Okines,Vandana G. Abramson,Philippe L. Bedard,Mafalda Oliveira,Volkmar Mueller,Amelia Zelnak,Michael DiGiovanna,Thomas Bachelot,A. Jo Chien,Ruth O'Regan,Andrew M Wardley,Alison Conlin,David Cameron,Lisa A. Carey,Giuseppe Curigliano,Karen A. Gelmon,Sibylle Loibl,Jo Al Mayor,Suzanne McGoldrick,Xuebei An,Eric P. Winer +28 more
TL;DR: In patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced riskof death by nearly half.
Journal ArticleDOI
Subtyping of triple-negative breast cancer: Implications for therapy
Vandana G. Abramson,Vandana G. Abramson,Brian D. Lehmann,Brian D. Lehmann,Tarah J. Ballinger,Jennifer A. Pietenpol,Jennifer A. Pietenpol +6 more
TL;DR: In this review, the authors discuss recent developments in subtyping TNBC and the current and upcoming therapeutic strategies being explored in an attempt to target TNBC.